Pay in 4 interest-free payments of $5.28 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Retatrutide is an investigational triple agonist still in active Phase 3 obesity development under Eli Lilly's J1I-MC-GZBJ master protocol, with no MHRA or EMA marketing authorisation as of 2026 [6][7]
Kaysan Owens, youll receive expert medical oversight and a caring team committed to your success
Gmez Morillas, A., Besson, V
Semaglutide treatment commenced at 0.25 mg per week for the initial 4 weeks using a pre-filled pen injector, with a fixed-dose escalation every 4 weeks until reaching the maintenance dose of 2.4 mg by week 16 (lower maintenance doses allowed if 2.4 mg was intolerable for participants)
Caution is also warranted in patients with a history of pancreatitis
US$ 25.62
US$ 20.04
US$ 21.83
US$ 24.54
US$ 27.16
